Sign In
Buy SVA
$6.47
+0 (+0%)
At Close: Feb 07, 2020
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
12:27pm, Wednesday, 09'th Jul 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long term shareholder of Sinovac B
Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2
03:26pm, Monday, 07'th Jul 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent share
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
01:46am, Monday, 07'th Jul 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
CORRECTING and REPLACING SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
11:39am, Wednesday, 02'nd Jul 2025
NEW YORK--(BUSINESS WIRE)--Third paragraph, second sentence of release should read: These include the current Board's failure to actively engage with management, its lack of sound financial reasoning
PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or “we”), a leading global investment firm focused exclusively on healthcare and life sciences and a long-term shareholder of Sinovac B
SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac
09:20am, Wednesday, 02'nd Jul 2025
NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”, “we” or “us”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”) which beneficial
Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place
01:03am, Wednesday, 02'nd Jul 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
SAIF Partners Sends Letter to Sinovac Shareholders
03:02pm, Tuesday, 01'st Jul 2025
NEW YORK--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15%
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today sent a let
SINOVAC Board of Directors Prevails Against Advantech/Prime's Lawsuit in Hong Kong
07:12pm, Friday, 27'th Jun 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board's Failure to Act in the Interests of Shareholders
04:13pm, Tuesday, 24'th Jun 2025
BEIJING--(BUSINESS WIRE)--SAIF Partners IV L.P., (“SAIF Partners”), the largest single investor in Sinovac Biotech Ltd. (“Sinovac” or the “Company”), beneficially owning approximately 15%
SINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder Interests
08:27am, Tuesday, 24'th Jun 2025
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced
